AIP
APRE icon

Ameritas Investment Partners’s Aprea Therapeutics APRE Stock Holding History

Ameritas Investment Partners’s Portfolio APRE Stock Details APRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-28
Closed -$3K – 3051
2021
Q1 		$3K Hold
28
– – ﹤0.01% 3050
2020
Q4 		$3K Hold
28
– – ﹤0.01% 3017
2020
Q3 		$13K Hold
28
– – ﹤0.01% 2581
2020
Q2 		$22K Hold
28
– – ﹤0.01% 2309
2020
Q1 		$19K Hold
28
– – ﹤0.01% 2199
2019
Q4 		$25K Buy
+28
New +$15.4K ﹤0.01% 2292

Other funds holding APRE

VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
SG Americas Securities
SG Americas Securities New York $92.9B AUM 36.98% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Voloridge Investment Management
Voloridge Investment Management Jupiter, Florida $25B AUM 28.08% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return

Ameritas Investment Partners's APRE Position: Q2 2021 in Review

Ameritas Investment Partners sold out of Aprea Therapeutics (APRE) in Q2 2021, closing a stake of 28 shares — an estimated $3K sold.

Ameritas Investment Partners first reported a position in APRE in Q4 2019 and held it in 6 quarters. The position peaked at $25K in Q4 2019. 50 funds tracked by Wall St. Rank hold APRE as of Q2 2021.

  • Ameritas Investment Partners reported no remaining Aprea Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Ameritas Investment Partners sold 28 Aprea Therapeutics shares in Q2 2021, an estimated $3K.
  • Ameritas Investment Partners first reported a position in Aprea Therapeutics in Q4 2019 and held it in 6 quarters.
  • Ameritas Investment Partners's Aprea Therapeutics position peaked at $25K in Q4 2019.
  • 50 funds tracked by Wall St. Rank held Aprea Therapeutics as of Q2 2021.

Based on Ameritas Investment Partners's 13F filing for Q2 2021, filed 6 Aug 2021.